From 315 oncologists, 188 responded (response rate 59.7%). BSA-based dosing is standard practice for 176 (97.2%) of the responding oncologists. In the adjuvant disease setting, 23 (12.7%) use ideal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback